Oncology Institute | 8-K: FY2025 Q3 Revenue: USD 136.56 M

Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.

EPS: As of FY2025 Q3, the actual value is USD -0.14.

EBIT: As of FY2025 Q3, the actual value is USD -14.58 M.

Segment Revenue

• Patient Services: Revenue of $60.2 million for Q3 2025, up from $49.8 million in Q3 2024.
• Dispensary: Revenue of $75.9 million for Q3 2025, up from $48.2 million in Q3 2024.
• Clinical Trials & Other: Revenue of $0.5 million for Q3 2025, down from $1.9 million in Q3 2024.

Operational Metrics

• Net Loss: $16.5 million for Q3 2025, compared to a net loss of $16.1 million in Q3 2024.
• Gross Profit: $18.9 million for Q3 2025, an increase of 31.7% from Q3 2024.
• Adjusted EBITDA: - $3.5 million for Q3 2025, compared to - $8.2 million in Q3 2024.

Cash Flow

• Cash and Cash Equivalents: $27.7 million as of September 30, 2025.
• Free Cash Flow: - $26.9 million for the nine months ended September 30, 2025, compared to - $29.4 million for the same period in 2024.

Unique Metrics

• Fee-for-Service Revenue Growth: 13% increase over Q3 2024, driven by organic growth in Florida and Oregon.

Outlook / Guidance

• The Oncology Institute, Inc. updated its full-year 2025 revenue guidance to $495 to $505 million, up from the previous guidance of $460 to $480 million.
• Adjusted EBITDA guidance for 2025 was updated to - $11 to - $13 million, from the previous range of - $8 to - $17 million.
• The company expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025.